Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04345068 · ClinicalTrials.gov registry record · NA

Calm for Cancer Sleep Disturbance

A NA study of Cancer, sponsored by Arizona State University.

Completed
Registry status
NA
Development phase
150
Enrollment target
1
Study location

NCT04345068: Completed NA study of Cancer, sponsored by Arizona State University.

NCT04345068 is a NA study of Cancer that has completed, run by Arizona State University. The registered enrollment target is 150 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04345068, a NA study of Cancer, has completed, sponsored by Arizona State University.

COMPLETED
Registry status
NA
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

Cancer and cancer treatment often lead patients and survivors to experience a host of chronic symptoms, of which sleep disturbances are a major concern. Smartphone-based meditation via an already-developed app (i.e., Calm) is a unique and novel way of providing a potentially helpful symptom-management strategy to cancer patients and survivors. Our hypothesis is that cancer patients/survivors using the Calm smartphone app for eight weeks will see improved sleep disturbance (primary outcome) as well as anxiety, depression, pain intensity, global health, quality of life, emotional regulation, and mindfulness when compared to a time and attention-matched health education podcast control group. Cancer patients/survivors (n=300) will be randomly assigned to an intervention or control group for eight weeks, with study outcome measurement occurring at baseline, post-intervention (i.e., week eight), and follow-up (i.e., week 20).

Primary Outcome

Sleep Disturbance will be measured with the NIH PROMIS Sleep Disturbance Adult Short Form. A higher score indicates more of the concept being measured.

Conditions Studied

Interventions

  • BEHAVIORAL Calm Meditation Mobile App
  • BEHAVIORAL Health Education Podcast Mobile App

Study Locations (1)

Arizona

  • Arizona State University - Phoenix

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2020-08-01
Est. Completion 2021-06-01
Phase NA
Arizona State University

187 total trials

What the finished NCT04345068 record still lists

NCT04345068 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Calm Meditation Mobile App is the first listed.

NCT04345068 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT04345068 about?

NCT04345068 is a clinical study titled "Calm for Cancer Sleep Disturbance". Cancer and cancer treatment often lead patients and survivors to experience a host of chronic symptoms, of which sleep disturbances are a major concern. Smartphone-based meditation via an already-developed app (i.e., Calm) is a unique and novel way of providing a potentially helpful symptom-manageme...

What is the current status of trial NCT04345068?

This trial is currently completed. It is a NA study. The enrollment target is 150 participants. The study started on 2020-08-01. Estimated completion is 2021-06-01.

What conditions does trial NCT04345068 study?

This clinical trial studies the following conditions: Cancer.

What interventions are being tested in trial NCT04345068?

The interventions under investigation include: Calm Meditation Mobile App (BEHAVIORAL), Health Education Podcast Mobile App (BEHAVIORAL).

Who is sponsoring clinical trial NCT04345068?

This trial is sponsored by Arizona State University, which has 187 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04345068 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04345068's enrollment target sits among peer trials

150 264th of 615 higher than 346 of 615 other Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04345068, the US trial registry maintained by the National Library of Medicine. NCT04345068 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.